Featured News
From Slides to Insights: Accelerating Research with AI-Powered Digital Pathology
Advance Drug Development with AI-Powered Digital Pathology
In drug development, time is critical. Every day saved in preclinical research can move promising therapies closer to patients faster. Because we understand that every moment matters, we are modernizing traditional workflows with digital pathology, helping clients move beyond manual processes to an integrated, AI-powered pathology ecosystem that accelerates insights, improves quality, and drives efficiency.
Digital pathology isn’t just about digitizing slides; it is about reengineering the entire workflow. by applying AI at critical bottlenecks and grounding our models in Charles River’s unmatched pathology expertise and image libraries, we are delivering faster, more scalable, and more insightful pathology for our clients.”
Histopathology has long been a time intensive process in preclinical studies, where manual slide review and fragmented systems stall critical decision-making. Our end-to-end integrated, AI-powered digital pathology platform streamlines the entire workflow, from tissue processing to interpretation, reducing delays while maintaining regulatory rigor. The result: faster turnaround times and earlier, more confident decisions.
Applying AI Where it Counts
By focusing AI-powered pathology on high-impact areas such as slide quality control, we eliminate manual bottlenecks and reduce the risk of downstream errors. Automated detection of imaging artifacts and quality issues enhances accuracy while freeing scientific teams to focus on deeper analysis and interpretation. At its core, this transformation delivers what matters most:
- Faster study timelines
- Greater operational efficiency
- Higher-quality insights
- Scalable solutions for evolving pipelines
AI-powered pathology provides a strategic advantage for clients advancing life-changing therapies, delivering a smarter, faster path forward.